Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JF6C
|
|||
| Drug Name |
Eltanexor oral
|
|||
| Synonyms |
KPT-8602; Eltanexor; UNII-Q59IQJ9NTK; Q59IQJ9NTK; 1642300-52-4; Eltanexor [INN]; Eltanexor [WHO-DD]; SCHEMBL16324809; MolPort-044-830-659; s8397; AKOS032945053; CS-5947; HY-100423; (E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide; 5-Pyrimidineacetamide, alpha-((3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)methylene)-, (alphaE)-; (2E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-enamide
Click to Show/Hide
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 1/2 | [1] | |
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1/2 | [1] | ||
| Prostate cancer [ICD-11: 2C82.0] | Phase 1/2 | [1] | ||
| Company |
Karyopharm Therapeutics Newton, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H10F6N6O
|
|||
| Canonical SMILES |
C1=C(C=C(C=C1C(F)(F)F)C(F)(F)F)C2=NN(C=N2)C=C(C3=CN=CN=C3)C(=O)N
|
|||
| InChI |
1S/C17H10F6N6O/c18-16(19,20)11-1-9(2-12(3-11)17(21,22)23)15-27-8-29(28-15)6-13(14(24)30)10-4-25-7-26-5-10/h1-8H,(H2,24,30)/b13-6+
|
|||
| InChIKey |
JFBAVWVBLRIWHM-AWNIVKPZSA-N
|
|||
| CAS Number |
CAS 1642300-52-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.